Lakefront Biotherapeutics NV LKFT
33.96 USD +1.81 (+5.63%)
Nov 4, 2026, 3:09 PM EST
32.85 Day range 33.96
25.68 52-week range 36.24
- YTD
- +3.85%
- 1 year
- +11.49%
Analyst view
Price target (mean) 30.41 -10.4% downside
Now 33.96
- Target (low)
- 21.27
- Target (mean)
- 30.41
- Target (high)
- 44.02
Ratings (0m) 6 2 buy · 3 hold · 1 sell
- Strong buy1
- Buy1
- Hold3
- Sell1
- Strong sell0
Recommendation trend
- This month 6
- 1 month ago 6
- 2 months ago 6
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | 0.23 | 0.23 – 0.23 | -0.178 | +229.2% | 41.18M | -42.1% | 1 |
| Next quarter | -0.165 | -0.54 – 0.21 | 12.27 | -101.3% | 106.78M | -88.1% | 2 |
| Current year | -0.71 | -0.71 – -0.71 | 10.21 | -107.0% | 117.22M | -89.5% | 1 |
| Next year | -1.06 | -1.75 – -0.37 | -0.71 | -49.3% | 84.62M | -27.8% | 2 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 23, 2026 | RBC Capital | Upgrade | Sector Perform | Outperform |
| Aug 11, 2026 | Morgan Stanley | Maintained | Equal-Weight | Equal-Weight |
| Aug 11, 2026 | RBC Capital | Maintained | Sector Perform | Sector Perform |
| Feb 25, 2026 | RBC Capital | Maintained | Sector Perform | Sector Perform |